Merck signs co-promotion agreement of ‘Glucophage & Concor’ with Yungjin Pharm

The Merck Korea’s biopharma department, a Korean subsidiary of Merck, signed a Korean co-promotion agreement of the primary treatment for diabetes type 2 ‘Glucophage/ Glucophage XR’ and the selective beta blocker ‘Concor’ with Yungjin Pharm on the 13^th.

Glucophage/ Glucophage XR(generic name: metformin), an oral antidiabetic, is a product widely known in the world. At the new guideline for dia...